Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior
- PMID: 15757934
- PMCID: PMC1761120
- DOI: 10.1377/hlthaff.24.2.483
Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior
Abstract
New genetic tests for adult-onset diseases raise concerns about possible adverse selection in insurance markets. To test for this behavior, we followed 148 cognitively normal people participating in a randomized clinical trial of genetic testing for Alzheimer's disease for one year after risk assessment and Apolipoprotein E (APOE) genotype disclosure. Although no significant differences were found in health, life, or disability insurance purchases, those who tested positive were 5.76 times more likely to have altered their long-term care insurance than those who did not receive APOE genotype disclosure. If genetic testing for Alzheimer's risk assessment becomes common, it could trigger adverse selection in long-term care insurance.
References
-
- Actuarial Standards Board. Actuarial Standard of Practice #12 Concerning Risk Classification, Section 2.1. (1989) 1. http://www.actuarialstandardsboard.org/pdf/asops/asop12_014.PDF, accessed on September 27, 2004.
-
- National Human Genome Research Institute, “Genetic Discrimination in Health Insurance.” Available at http://www.genome.gov/10002328#1, accessed September 28, 2004.
-
- Centers for Medicare and Medicaid Services, “The Health Insurance Portability and Accountability Act of 1996 (HIPAA).” Available at http://www.cms.hhs.gov/hipaa/, accessed September 28, 2004.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous